#VisualAbstract: Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: cabozantinib
Atezolizumab added to cabozantinib does not improve clinical outcomes in patients with metastatic renal cell carcinoma
1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more ...
#VisualAbstract: Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
1. The probability of progression-free survival at 12 months was 0.57 in the experimental group (cabozantinib plus nivolumab and ipilimumab) ...
Telaglenastat addition to cabozantinib did not demonstrate benefit in pre-treated advanced renal cell carcinoma
1. Telaglenastat addition to cabozantinib did not show improvements in clinical benefit. 2. Adverse events of grades 3 or 4 ...
Cabozantinib may be a viable first-line treatment in metastatic renal cell collecting duct carcinoma
1. Objective response rate was 35%, with 1 patient showing a complete response and 7 showing a partial response. 2. ...
Cabozantinib is associated with an intracranial response in the treatment of brain metastases from renal cell carcinoma
1. Intracranial response rate of 55% was reported in patients receiving cabozantinib with progressing brain metastases with no concomitant brain-directed ...
#VisualAbstract: Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...
![Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2016/01/Papillary_renal_cell_carcinoma_-_very_high_mag-350x250.jpg)
Nivolumab and cabozantinib superior to sunitinib for advanced renal-cell carcinoma
1. The combination of nivolumab and cabozantinib was superior to sunitinib in untreated advanced renal-cell carcinoma 2. The combination treatment ...
Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
